Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
CSPC Pharmaceutical Group ( (HK:1093) ) has issued an update.
CSPC Pharmaceutical Group announced that its pivotal Phase II/III clinical study of KN026, a recombinant humanised anti-HER2 bispecific antibody, met the primary endpoint of progression-free survival with statistical significance. This development, particularly for patients with HER2-positive gastric or gastroesophageal junction adenocarcinoma, highlights KN026’s potential to improve treatment outcomes and reinforces CSPC’s position in the oncology drug market.
More about CSPC Pharmaceutical Group
CSPC Pharmaceutical Group is a Hong Kong-based company operating in the pharmaceutical industry. It focuses on developing innovative drugs, particularly in the field of oncology, with a strong emphasis on creating treatments for cancers such as gastric and gastroesophageal junction adenocarcinoma.
YTD Price Performance: 8.47%
Average Trading Volume: 35,356
Technical Sentiment Signal: Buy
Current Market Cap: $8.97B
Find detailed analytics on 1093 stock on TipRanks’ Stock Analysis page.